Adaptimmune raises $104m series-A

NEA was joined in the round by a mix of European and US investors, namely OrbiMed, Wellington Partners, Fidelity Biosciences, Ridgeback Capital Management, Novo, QVT, Rock Springs Capital, venBio and Merlin Nexus.

Guggenheim Securities acted as placement agent for the funding round.

The substantial capital injection will be used by Adaptimmune to further fund its current internal programmes. The company is currently running trials in the US for multiple myeloma, melanoma, sarcoma and ovarian cancer.

In conjunction with the round, former Bristol Myers-Squibb CSO and executive vice president Elliott Sigal has joined the company's board of directors as an independent industry representative.

Company
Founded in 2008, Adaptimmune is headquartered in Oxford with a clinical base in Philadelphia in the US. The company focuses on the use of T-cell therapy to treat cancer and infectious diseases.

It recently entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialisation of its NY-ESO-1 clinical cancer programme.

People
James Noble is the CEO of Adaptimmune. NEA partner and healthcare head David Mott has joined the company's board of directors alongside Ali Behbahani, a partner on NEA's healthcare team, and OrbiMed partner Peter Thompson.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Healthcare
• United Kingdom
• Wellington Partners
• Foresight Group
• United States